Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Editors Pick
    • 9 more formulations...

    9 more formulations including Methylprednisolone Inj under Price Ceiling: NPPA order

    Written by Ruby Khatun Khatun Published On 2018-02-16T15:52:17+05:30  |  Updated On 16 Feb 2018 3:52 PM IST
    9 more formulations including Methylprednisolone Inj under Price Ceiling: NPPA order

    New Delhi: Through a recent notification, National Pharmaceutical Pricing Authority (NPPA), Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, Government of India has fixed the ceiling prices of 09 formulations under the Drugs (Prices Control) Order, 2013 exclusive of goods and services tax (GST).


    The notice states that in the exercise of the powers conferred by paragraphs 4, 6, 10, 11, 14, 16, 17 and 18 of the Drugs (Prices Control) Order, 2013, read with S.O. 1394(E) dated the 30th May 2013 and S.O. 701(E) dated 10th March, 2016 issued by the Government of India in the Ministry of Chemicals and Fertilizers, and in supersession of the Order(s) of the Government of India in the Ministry of Chemicals and Fertilizers (National Pharmaceutical Pricing Authority) specified in the Column (7) of the table regarding formulation specified in mentioned in the table in so far as it relates to formulation pack mentioned in the table below, except in respect of things done or omitted to be done before such supersession, the National Pharmaceutical Pricing Authority, hereby fixes/revises the price as specified in column (5) of the table herein below as ceiling price exclusive of goods and services tax applicable, if any, in respect of the Scheduled formulation(s) specified in the corresponding entry in column (2) of the said Table with the dosage form & strength and unit specified respectively in the corresponding entries in columns (3) and (4) thereof:


    Following are the details










































































































    Sl.NoName of the
    Scheduled
    Formulation
    Dosage form &
    Strength
    UnitCeiling
    Price (Rs.)
    Review Order
    number and
    date
    Existing SO number
    and date
    (1)(2)(3)(4)(5)(6)(7)
    1.ClomipheneTablet 50mg1 Tablet7.5631015/36/2017-
    Pricing dated
    24.8.2017
    2058(E) dated 30.6.2017
    (at Sl. No. 146)
    2.ClomipheneTablet 100mg1 Tablet11.0831015/36/2017-
    Pricing dated
    24.8.2017
    2058(E) dated 30.6.2017
    (at Sl. No. 147)
    3.AdenosineInjection 3mg/ml1 ML89.3431015/12/2017-
    Pricing dated
    28.9.2017 &
    31015/39/2017-
    Pricing dated
    24.8.2017
    2058(E) dated 30.6.2017
    (at Sl. No. 15)
    4.Povidone IodineSolution 10%1 ML0.7631015/34/2017-
    Pricing dated
    28.9.2017 & 31015/20/2017-Pricing dated 28.9.2017
    2058(E) dated 30.6.2017
    (at Sl. No. 490)
    5.MethylprednisoloneInjection 40mg/ml1 ML48.9731015/26/2017-
    Pricing dated
    30.10.2017
    2400(E) dated 28.7.2017
    (at Sl. No. 23)
    6.Sodium ValproateCR Tablets 300mg1
    Tablet
    5.7131015/68/2017-Pricing dated
    28.11.2017 & 31015/69/2017-Pricing dated
    28.11.2017
    2058(E) dated 30.6.2017
    (at Sl. No. 556)
    7.Sodium ValproateCR Tablets 500mg1
    Tablet
    8.8531015/68/2017-Pricing dated
    28.11.2017 &
    31015/69/2017-Pricing dated
    28.11.2017
    2058(E) dated 30.6.2017
    (at Sl. No. 555)
    8.Isosorbide 5
    Mononitrate
    Tablet 20 mg1
    Tablet
    2.9831015/31/2017-
    Pricing dated
    28.11.2017 &
    31015/39/2017-
    Pricing dated
    24.08.2017
    2058(E) dated 30.6.2017
    (at Sl. No. 314)
    9.LignocaineTopical Forms 2-
    5%
    1 gm or
    1 ml
    0.9831015/44/2017-
    Pricing dated
    28.11.2017
    2058(E) dated 30.6.2017
    (at Sl. No. 354)


    The manufacturers of above said scheduled formulations shall furnish quarterly return to the NPPA, in respect of production/import and sale of scheduled formulations in Form - III of Schedule - II of the DPCO, 2013 through IPDMS.


    Any manufacturer intending to discontinue production of said scheduled formulation shall furnish information to the NPPA, in respect of discontinuation of production and/or import of scheduled formulation in Form -IV of Schedule - II of the DPCO, 2013 at least six months prior to the intended date of discontinuation.


    The manufacturers not complying with the ceiling price and notes specified shall be liable to deposit the overcharged amount along with interest thereon under the provisions of the Drugs (Prices Control) Order, 2013 read with Essential Commodities Act, 1955.


    Consequent to the issue of ceiling prices of such formulations as specified, the price order(s) fixing ceiling or retail price, if any, issued prior to the above said date of notification, stand(s) superseded.


    Medical Dialogues had earlier reported that NPPA had fixed the retail Prices of 30 formulations under DPCO 2013 exclusive of goods and services tax (GST).


    Read also: NPPA fixes retail prices of 30 formulations, including Insulin, Metoprolol ER; check out details

    ceiling pricesDepartment of PharmaceuticalsDPCODrugs Prices Control OrderfixesGoods and Services TaxGovernment of IndiaGSTMinistry of Chemicals and FertilizersNational Pharmaceutical Pricing AuthorityNPPA

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Ruby Khatun Khatun
    Ruby Khatun Khatun
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok